SCHEMBL5010593

SCHEMBL5010593

Cc1cc(Nc2ccccc2C(N)=O)n(-c2ccc(Cl)cc2)n1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.61
MAPT P10636 6/20 0.59
GAA P10253 6/20 0.57
HPGD P15428 4/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
KMT2A Q03164 3/20 0.55
MEN1 O00255 2/20 0.55
LMNA P02545 3/20 0.53
HTT P42858 2/20 0.53
ALOX12 P18054 1/20 0.53
ALPG P10696 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
NTRK1 P04629 2/20 0.52
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
NPY1R P25929 1/20 0.50
NPY2R P49146 1/20 0.50
FTO Q9C0B1 1/20 0.49
TP53 P04637 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008476 0.91 GFER (0.64) GFERMAPTGAAHPGDSMN1; SMN2
SCHEMBL5005273 0.86 GFER (0.82) GFERMAPTGAAHPGDKMT2A
SCHEMBL5008344 0.81 GFER (0.52) GFERMAPTGAAHPGDKMT2A
SCHEMBL5008346 0.80 GFER (0.80) GFERMAPTGAAHPGDSMN1; SMN2
SCHEMBL5008355 0.78 CDK8 (0.63) GFERCYP2D6CYP2C9
SCHEMBL1819140 0.77 GFER (0.71) GFERMAPTGAAHPGDSMN1; SMN2
SCHEMBL6343958 0.76 GFER (0.73) GFERMAPTGAAHPGDSMN1; SMN2
SCHEMBL1514870 0.76 GFER (1.00) GFERMAPTGAAHPGDKMT2A
SCHEMBL5010717 0.75 MAPK14 (0.57) GAASMN1; SMN2NTRK1
SCHEMBL5010571 0.75 GFER (0.59) GFERMAPTGAAHPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2008-03-13 US disclosed
US-7265144-B2 Anilinopyrazole derivatives useful for the treatment of diabetes BAYER PHARMACEUTICALS CORPORATION (US) 2007-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064734-A1 Anilinopyrazole derivatives useful for the treatment of diabetes IAPP, GLP1R, GPR119 GFER 1604/4885MAPT 2420/4885GAA 385/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.